Clinical Trials for Other Solid Tumor

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with EGFR-mutated, advanced nonsquamous non-small cell lung cancer who have progressed after EGFR tyrosine kinase inhibitor therapy, comparing the investigational antibody-drug conjugate sacituzumab tirumotecan, which targets TROP2, to the standard chemotherapy regimen of pemetrexed plus carboplatin.

ClinicalTrials.gov ID: NCT06305754

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets patients with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (≥ 50%) and without actionable genomic alterations, comparing the efficacy of Datopotamab Deruxtecan (an ADC targeting TROP2) combined with rilvegostomig (a bispecific antibody targeting PD-1 and TIGIT), versus rilvegostomig or pembrolizumab monotherapy.

ClinicalTrials.gov ID: NCT06357533

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves patients with locally advanced or metastatic NSCLC that have EGFR exon 20 insertions or uncommon EGFR mutations, including those with active brain metastasis, and evaluates the safety and efficacy of zipalertinib, an oral irreversible tyrosine kinase inhibitor targeting mutant EGFR. Participants receive zipalertinib twice daily, with primary outcomes focusing on objective response rate and multiple secondary endpoints related to treatment safety and efficacy.

ClinicalTrials.gov ID: NCT05967689

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates patients with Stage IIIB, IIIC, or Stage IV NSCLC without actionable EGFR mutations or ALK rearrangements, using BNT327, a bispecific antibody targeting PD-L1 and VEGF-A, in combination with chemotherapy and other investigational agents. Standard chemotherapy agents like Carboplatin, Pemetrexed, Paclitaxel, and Pembrolizumab are also employed, aiming to assess efficacy and safety in first-line treatment.

ClinicalTrials.gov ID: NCT06712316

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (TPS ≥ 50%)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial investigates ivonescimab, a bispecific antibody targeting PD-1 and VEGF, versus pembrolizumab in adult patients with metastatic non-small cell lung cancer with high PD-L1 expression (TPS ≥ 50%), aiming to assess treatment efficacy and safety in those without prior systemic treatment.

ClinicalTrials.gov ID: NCT06767514

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial targets patients with advanced ALK-positive non-small cell lung cancer who have not previously received specific treatments for NSCLC or ALK, comparing the efficacy of the novel ALK-selective tyrosine kinase inhibitor neladalkib (NVL-655) with alectinib in prolonging progression-free survival.

ClinicalTrials.gov ID: NCT06765109

A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves treatment-naïve patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with high PD-L1 expression (TPS ≥50%) and no actionable genomic alterations, comparing the efficacy and safety of the combination of datopotamab deruxtecan (Dato-DXd), an investigational TROP2-targeting antibody-drug conjugate, with pembrolizumab versus pembrolizumab alone.

ClinicalTrials.gov ID: NCT05215340

A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial targets treatment-naive patients aged 18 or older with stage IIIC or IV non-small cell lung cancer (NSCLC) that is metastatic or recurrent, with PD-L1 expression ≥1% and no known alterations in EGFR, ALK, ROS1, or RET. It evaluates the efficacy and safety of combining the investigational CXCR1/2 inhibitor SX-682, which modulates the tumor microenvironment, with the anti-PD-1 antibody pembrolizumab.

ClinicalTrials.gov ID: NCT05570825

A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial focuses on patients with Stage IV metastatic non-small cell lung cancer who have an ECOG performance status of 0 to 1 and includes treatments combining domvanalimab (a TIGIT inhibitor), zimberelimab (a PD-1 inhibitor), quemliclustat (a CD73 inhibitor), and platinum-based chemotherapy. The study aims to assess their efficacy and safety in enhancing immune responses and overcoming tumor immunosuppression.

ClinicalTrials.gov ID: NCT05676931

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with c-Met overexpressing, EGFR wildtype, locally advanced or metastatic non-squamous NSCLC who have progressed on prior therapies and compares treatment with telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, against standard chemotherapy with docetaxel.

ClinicalTrials.gov ID: NCT04928846